Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fudan AC: Adjuvant Chemotherapy in Rectal Cancer
NCT03415763Phase 3Recruiting
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in rectal cancer. Started Nov 2018; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03415763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415763.